Market Intelligence, Clinical Progress, and High-Purity Reagents for PGE2 Modulation and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HPGD (15-PGDH) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HPGD Active Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. NAD+ binding site intact. |
View HPGD Products |
| Gene Delivery | HPGD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HPGD Products |
| Benchmark Ab | Anti-HPGD Antibody Recombinant positive control for western blot and IHC. |
View HPGD Products |
| Validator | HPGD siRNA Set For knockdown verification in cell-based functional assays. |
View HPGD Products |
| Related Target A | PTGS2 (COX-2) Upstream enzyme controlling PGE2 synthesis, critical for counter-screening and pathway validation. |
View PTGS2 Products |
| Related Target B | PTGER4 (EP4) Primary downstream PGE2 receptor driving tissue regeneration signals. |
View PTGER4 Products |
| Related Target C | PTGES (mPGES-1) Terminal PGE2 synthase; compensatory pathway analysis. |
View PTGES Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Maintenance | Strictly formulated Recombinant HPGD preserving native dehydrogenase conformation; suitable for SPR & Thermal Shift. |
| Cross-species Translation (Mouse Models) | Human/Mouse/Rat ortholog proteins available with >95% purity for matched screening. |
| Lack of Validated Pathway Controls | Associated PTGS2 and PTGER proteins available for holistic PGE2 pathway mapping. |
| False Positives in Phenotypic Screens | Sequence-verified siRNA included for precise genetic target validation. |
| Selectivity vs. SDR Family | Homolog panel proteins (AKR1C3, HSD11B2) strictly verified by mass spec for cross-reactivity screening. |
Live HPGD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HPGD (15-hydroxyprostaglandin dehydrogenase) represents a paradigm shift in regenerative medicine. By inhibiting HPGD, researchers can safely elevate local tissue levels of Prostaglandin E2 (PGE2) without the systemic toxicity of direct PGE2 administration. The race for HPGD therapeutics is intensifying, with major players shifting focus from early validation to optimizing highly potent, orally bioavailable small molecules. As first-generation therapies advance through preclinical and early clinical stages for Inflammatory Bowel Disease (IBD) and Idiopathic Pulmonary Fibrosis (IPF), the next wave of R&D is targeting localized delivery and combinations with stem cell transplants for bone marrow engraftment. Additionally, combination approaches with NSAIDs to compartmentalize PGE2 signaling and structural biology efforts to exploit the unique substrate channel for allosteric inhibition are emerging.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Case Western/Rodeo Therapeutics (Amgen), Gossamer Bio, Novartis | Ulcerative Colitis, Pulmonary Fibrosis, IBD | High-throughput Enzymatic Assay (Need High-purity Active Recombinant HPGD) |
| PROTAC / Degrader | Academic Consortia | Tissue Regeneration | Ternary Complex Formation (Need carefully tagged, native-folded HPGD) |
| Gene Therapy (siRNA) | Various Preclinical Labs | Wound Healing, Dermatology | Knockdown Validation (Need Sequence Verified Antibodies & siRNA) |
| Regenerative Therapy | Wound Care Biotechs | Chronic Wounds, Bone Fracture | Cell-based PGE2 Accumulation Assay (Need stable cell lines via Lentivirus) |
| Biomarker Development | Diagnostic Partners | Colorectal Cancer Screening | Quantitative ELISA Standards (Need purified antigen with confirmed concentration) |
Key Mutations and Functional Insights
HPGD mutations relevant to drug discovery include:
- rs121434480: In COA; inactive; evidence from UniProt P15428 VAR_046209.
- rs121434481: In DIGC; evidence from UniProt P15428 VAR_060792.
- rs140209262: Evidence from UniProt P15428 VAR_006972.
These mutations are critical for understanding enzyme activity and designing selective inhibitors.